NEW YORK (GenomeWeb News) – Qiagen today said that GE company Clarient will offer its therascreen KRAS RGQ PCR kit as a companion diagnostic.

Clarient will offer the test to help guide the use of Erbitux (cetuximab) for treating patients with metastatic colorectal cancer. Clarient chose the therascreen KRAS assay and Qiagen's Rotor-Gene Q molecular diagnostic platform after the US Food and Drug Administration approved the test in July, Qiagen said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."

The US Food and Drug Administration has approved four molecularly targeted drugs this month, suggesting that personalized medicine has "turned a corner."

In Science this week: caution urged in use of gene drives, and more.